Skip to Content

Generic Emend Availability

Emend is a brand name of aprepitant, approved by the FDA in the following formulation(s):

EMEND (aprepitant - capsule;oral)

  • Manufacturer: MERCK
    Approval date: March 26, 2003
    Strength(s): 80MG [AB], 125MG [RLD] [AB]
  • Manufacturer: MERCK
    Approval date: June 30, 2006
    Strength(s): 40MG [AB]

EMEND (aprepitant - for suspension;oral)

  • Manufacturer: MSD MERCK CO
    Approval date: December 17, 2015
    Strength(s): 125MG/KIT [RLD]

Has a generic version of Emend been approved?

A generic version of Emend has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Emend and have been approved by the FDA:

aprepitant capsule;oral

  • Manufacturer: SANDOZ
    Approval date: September 24, 2012
    Strength(s): 40MG [AB], 80MG [AB], 125MG [AB]

Note: No generic formulation of the following product is available.

  • aprepitant - for suspension;oral

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Emend. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Polymorphic form of a tachykinin receptor antagonist
    Patent 6,096,742
    Issued: August 1, 2000
    Inventor(s): Crocker; Louis & McCauley; James
    Assignee(s): Merck & Co., Inc.
    This invention is concerned with a novel polymorphic form of the compound 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)-phenyl)-ethoxy)-3-(S)-(4-fluoro)phe nyl-4-(3-(5-oxo-1H,4H-1,2,4-triazolo)methylmorpholine which is a tachykinin receptor antagonist useful in the treatment or prevention of disorders of the central nervous system, inflammatory diseases, pain or migraine, asthma, and emesis. The instant polymorphic form has advantages over the other known forms of 2-(R)-(1-(R)-(3,5-bis(trifluoro-methyl)-phenyl)ethoxy)-3-(S)-(4-fluoro)phe nyl-4-(3-(5-oxo-1H,4H-1,2,4-triazolo)methylmorpholine in terms of thermodynamic stability and suitability for inclusion in pharmaceutical formulations.
    Patent expiration dates:
    • July 1, 2018
      ✓ 
      Patent use: TREATMENT OR PREVENTION OF EMESIS
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • July 1, 2018
      ✓ 
      Patent use: FOR THE PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH CHEMOTHERAPY
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • July 1, 2018
      ✓ 
      Patent use: PREVENTION OF POST-OPERATIVE NAUSEA AND VOMITING
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • July 1, 2018
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • July 1, 2018
  • Pharmaceutical composition of a tachykinin receptor antagonist
    Patent 8,258,132
    Issued: September 4, 2012
    Inventor(s): Bosch; H. William & Liversidge; Elaine & Shelukar; Suhas D. & Thompson; Karen C.
    Assignee(s): Merck Sharp & Dohme Corp.
    The present invention is directed to novel pharmaceutical compositions of the compound 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluoro)phenyl-4-(3-(5-oxo-1H,4H-1,2,4-triazolo)methylmorpholine. The pharmaceutical compositions of this invention useful in the treatment or prevention of disorders such as psychiatric disorders including depression and anxiety, inflammatory diseases and emesis.
    Patent expiration dates:
    • September 26, 2027
      ✓ 
      Patent use: PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING
      ✓ 
      Drug product
    • September 26, 2027
      ✓ 
      Patent use: FOR THE PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH CHEMOTHERAPY
      ✓ 
      Drug product

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • August 28, 2018 - NEW PATIENT POPULATION

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
ABProducts meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (i.e., identical active ingredients(s), dosage form, and route(s) of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (i.e., AB1, AB2, AB3, etc.). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against.
Hide